[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hyperthyroidismthyrotoxicosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hyperthyroidismthyrotoxicosis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100594320","evaluating-an-ai-tool-for-detecting-thyrotoxic-states-100594320",false,"NCT07017907","Evaluating an AI Tool for Detecting Thyrotoxic States","Performance Evaluation of the Software Medical Device to Detect the Thyrotoxic State in Patients With Hyperthyroidism","Inclusion Criteria:\n\n* Adults aged 22 years or older, regardless of sex.\n* Individuals who are newly diagnosed with Graves' disease or currently undergoing treatment for it.\n* Individuals who have received sufficient explanation about the investigational software and are able to use it appropriately.\n* Individuals who voluntarily agree to participate in the study and have signed informed consent, either directly or via a legally authorized representative.\n\nExclusion Criteria:\n\n* Individuals with cardiac conditions such as arrhythmia or heart failure.\n* Individuals taking medications that significantly affect heart rate, including antiarrhythmics or antihistamines. (Intermittent short-acting beta-blockers are allowed.)\n* Pregnant or breastfeeding individuals, or those planning pregnancy during the study period or not using appropriate contraception.\n* Individuals with significant comorbidities that interfere with follow-up or study compliance.\n* Individuals with severe psychiatric disorders, substance use disorder, or alcohol dependence.\n* Individuals deemed ineligible at the discretion of the investigator for safety or ethical concerns.","ALL","22 Years",{"count":19,"type":20},15,"ESTIMATED","12 Weeks","OBSERVATIONAL","This observational study aims to evaluate the performance of a software-based medical device, Glandy HYPER, in detecting the thyrotoxic state in patients with hyperthyroidism. The device utilizes heart rate data collected from commercially available wearable devices and compares it with thyroid function test results. The study will enroll patients diagnosed with Graves' disease, monitoring their heart rate during sleep and correlating these measurements with free T4 levels obtained through serial blood testing. No investigational device output will be disclosed to participants, and the study will not alter standard clinical care.",[25,26],"Graves Disease","Hyperthyroidism\u002FThyrotoxicosis",[28,29,30,31,32,33,34],"Graves disease","Hyperthyroidism","Thyrotoxicosis","Artificial intelligence","Heart rate","SaMD","wearable device","RECRUITING","2026-05-28",{"date":38,"type":39},"2026-06-01","ACTUAL",{"date":41,"type":39},"2026-01-09",{"date":43,"type":20},"2026-12-31",{"name":45,"class":46},"THYROSCOPE INC.","INDUSTRY",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":47},"100635832","efficacy-of-thermal-ablation-combined-with-antithyroid-drugs-in-the-treatment-of-primary-hyperthyroidism-100635832","NCT07557810","Efficacy of Thermal Ablation Combined With Antithyroid Drugs in the Treatment of Primary Hyperthyroidism","Multicenter Study on the Efficacy of Thermal Ablation Combined With Antithyroid Drugs in the Treatment of Primary Hyperthyroidism","Inclusion Criteria:\n\n* Patients diagnosed with primary hyperthyroidism based on clinical manifestations and laboratory findings;\n* Patients whose basal metabolic rate (BMR) remains within ±20% of the normal reference range, and whose resting heart rate is controlled at ≤90 beats\u002Fmin;\n* Patients with inadequate response to standard antithyroid drug (ATD) therapy, those experiencing severe adverse reactions to ATDs, those unsuitable for or unresponsive to radioactive iodine (RAI) therapy, or those who decline conventional surgical resection and wish to undergo ablation combined with medication to shorten the treatment course and achieve rapid improvement of hyperthyroid symptoms, including patients with mild, moderate, or severe disease;\n* Patients with concomitant moderate-to-severe Graves' ophthalmopathy (GO);\n* Patients with a safe needle trajectory for ablation access;\n* Patients who are able to understand the purpose of the study, voluntarily participate, and provide written informed consent.\n\nExclusion Criteria:\n\n* Severe coagulopathy;\n* Poor general condition, such as concomitant severe cardiac, hepatic, renal, or other major organ dysfunction;\n* Substernal goiter or a thyroid gland largely located in the retrosternal space (relative contraindication; staged treatment may be considered);\n* Patients with malignant exophthalmos in whom the condition may worsen post-procedure;\n* Patients with significant tracheal compression requiring urgent decompression;\n* Unilateral vocal cord dysfunction confirmed by laryngoscopy;\n* Women in the first or third trimester of pregnancy, lactating women, or those planning pregnancy in the near future.","80 Years",{"count":57,"type":20},454,"Hyperthyroidism is a clinical syndrome caused by excessive production of thyroid hormones, leading to accelerated metabolism and increased excitability of multiple organ systems. Patients commonly present with polyphagia, weight loss, palpitations, and sweating. Primary hyperthyroidism is a common endocrine disorder traditionally treated with anti-thyroid drugs (ATD), radioactive iodine (¹³¹I), or surgery.\n\nWhile ATD can rapidly inhibit thyroid hormone synthesis and control symptoms, long-term use carries risks of liver damage and bone marrow suppression. Radioactive iodine involves risks of recurrence or permanent hypothyroidism, and thyroidectomy-though effective-is associated with significant trauma, potential complications, and cervical scarring. Given the limitations of these monotherapies, a combined approach leveraging thermal ablation as an adjunct to antithyroid drug therapy has emerged as a promising strategy for both rapid symptom control and long-term management.\n\nWith advances in minimally invasive techniques, thermal ablation combined with pharmacotherapy offers a balanced solution. Thermal ablation-including microwave and radiofrequency ablation-provides high precision, minimal invasiveness, and rapid recovery by directly destroying hyperfunctioning thyroid tissue under ultrasound guidance. When paired with a tailored antithyroid drug regimen, this approach not only secures immediate stabilization of thyroid function but also reduces the required drug dosage and duration, thereby mitigating drug-related adverse effects. This combined strategy maintains the cosmetic and cost-effective advantages of ablation while addressing the need for sustained endocrine control.\n\nStudies have demonstrated that thermal ablation combined with antithyroid drugs effectively normalizes T3 and T4 levels, alleviates hypermetabolic symptoms such as palpitations and sweating, and significantly improves quality of life with a low complication rate. This integrated model is suitable for initial treatment, recurrent or refractory cases, and is particularly advantageous for patients with reduced cardiopulmonary reserve or advanced age.\n\nHowever, current evidence is largely derived from single-center studies, and high-quality multicenter data are needed to validate this combined strategy. This study aims to prospectively collect baseline data from patients undergoing thermal ablation in conjunction with antithyroid drug therapy across multiple centers. The objectives are to evaluate the efficacy and safety of this combined modality, explore the factors influencing the prognosis of ablation in a medicated context, optimize postoperative medication adjustment protocols, and provide high-quality evidence to guide the standardization and clinical dissemination of this synergistic approach.",[60,61,26,62],"Complication Rate","Efficacy and Safety","Cure Rate",[64],"Thermal Ablation","2026-04-25",{"date":67,"type":39},"2026-04-29",{"date":69,"type":39},"2025-02-13",{"date":71,"type":20},"2029-12-01",{"name":73,"class":74},"Chinese PLA General Hospital","OTHER",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":84,"studyType":22,"phases":4,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":47},"100576012","evaluation-of-different-diagnostic-therapeutic-strategies-in-patients-with-thyroid-pathology-100576012","NCT06779747","Evaluation of Different Diagnostic Therapeutic Strategies in Patients with Thyroid Pathology","Inclusion Criteria:\n\n* Age older than 18 years at the time of diagnosis;\n* Patients with thyroid pathology (hypothyroidism, hyperthyroidism\u002Fthyrotoxicosis, benign thyroid nodule, and thyroid carcinoma) in whom the diagnosis was made in our Center or another Center from 01\u002F01\u002F1995 until the approval of this study (retrospective phase) or from the time of approval of this study to the next 10 years (prospective phase);\n* Obtaining informed consent.\n\nExclusion Criteria:\n\n* Follow up lasting less than 3 months;\n* Incomplete or missing clinical data that may affect the correct assessment of the patient.","18 Years",{"count":83,"type":20},5850,"20 Years","Observational single-center prospective and retrospective, nonpharmacological, spontaneous cohort study.",[87,26,88,89],"Hypothyroidism","Thyroid Nodule (Benign)","Thyroid Carcinoma","2025-01-13",{"date":92,"type":39},"2025-01-17",{"date":94,"type":39},"2021-12-30",{"date":96,"type":20},"2041-12-30",{"name":98,"class":74},"IRCCS Azienda Ospedaliero-Universitaria di Bologna"]